Expert review of anticancer therapy · 2026
The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Micha John P, Bohart Randy D, Goldstein Bram H
Аннотация
INTRODUCTION: Endometrial cancer is the most frequently diagnosed gynecologic malignancy. Despite favorable clinical outcomes associated with early-stage disease, advanced or recurrent endometrial cancer is significantly more aggressive and coincides with inauspicious survival rates.
AREAS COVERED: Since endometrial cancer often develops in patients with obesity and type 2 diabetes, studies have evaluated metformin as a treatment for this neoplasm. Alternatively, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which mimic the GLP-1 peptide, may confer a decreased risk for endometrial cancer and represent a novel and promising anti-neoplastic therapy. In the current mini-review, we recount the preclinical results abstracted from studies identified via the PUBMED database from 2016-2026, with an emphasis on GLP-1 RAs in the treatment of endometrial cancer.
EXPERT OPENION: Preclinical data suggest that GLP-1 RAs avert progesterone resistance, augment the effects of hormone therapy, and prevent chemoresistance, not to mention bestow a substantive benefit in the adjuvant treatment of endometrial cancer. Currently, however, the results associated with GLP-1 RAs in treating malignancies are preliminary and warrant further investigation with randomized clinical trials.
AREAS COVERED: Since endometrial cancer often develops in patients with obesity and type 2 diabetes, studies have evaluated metformin as a treatment for this neoplasm. Alternatively, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which mimic the GLP-1 peptide, may confer a decreased risk for endometrial cancer and represent a novel and promising anti-neoplastic therapy. In the current mini-review, we recount the preclinical results abstracted from studies identified via the PUBMED database from 2016-2026, with an emphasis on GLP-1 RAs in the treatment of endometrial cancer.
EXPERT OPENION: Preclinical data suggest that GLP-1 RAs avert progesterone resistance, augment the effects of hormone therapy, and prevent chemoresistance, not to mention bestow a substantive benefit in the adjuvant treatment of endometrial cancer. Currently, however, the results associated with GLP-1 RAs in treating malignancies are preliminary and warrant further investigation with randomized clinical trials.